Business Wire

VALBIOTIS Announces Positive Results From the Phase IIA Clinical Study of VALEDIA®, Now the First Product Proven Effective in People With Prediabetes

Share

Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/PME eligible), Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced positive results (topline data) for the Phase IIA study1 of VALEDIA® (active substance: TOTUM-63), which evaluated this product's efficacy in a prediabetic population, compared to placebo. In this population, VALEDIA® significantly reduced fasting and post-prandial blood glucose levels, the two main risk factors for type 2 diabetes and the primary and secondary endpoints of the study, respectively. VALEDIA® also significantly reduced body weight and waist circumference. Thanks to these results, VALEDIA® is the first clinically validated product designed for prediabetic people, to reduce several risk factors for type 2 diabetes. These results enable the concomitant launch of the last two Phase IIB clinical studies (REVERSE-IT and PREVENT-IT), to obtain the first health claims for the risk reduction of type 2 diabetes in Europe and North America. This regulatory process does not require a Phase III study. Commercialization is planned for 2021, as previously announced.

Professor Jean-Marie BARD, Hospital Practitioner and Professor of Fundamental and Clinical Biochemistry at the University of Nantes, scientific expert for the study comments, "The reduction of fasting blood glucose and blood glucose 2 hours after a glucose intake is a new advance for prediabetics. These results show the impact of VALEDIA® on metabolism, with even a decrease in body weight and waist circumference, usually hard to demonstrate in clinical studies. With such data, VALEDIA® proves its efficacy to reduce type 2 diabetes risk factors.“

Murielle CAZAUBIEL, member of the board and Director of Development and Medical Affairs at VALBIOTIS, adds: "VALEDIA® was designed to carry out multiple actions on several metabolic targets, thanks to an original plant-based composition. This innovation has had clinical success in people with prediabetes: we now know that VALEDIA® acts on risk factors for type 2 diabetes. This study is a great success, and we'd like to express our thanks to all the volunteers who participated."

Main results of the VALEDIA® Phase IIA clinical study in prediabetic people

This multicenter study, conducted in Europe, evaluated TOTUM-63, the active ingredient of VALEDIA®, in prediabetic people for 6 months. It was a randomized, double-blind, placebo-controlled study. Included subjects received a daily dose of 5 grams of VALEDIA® while the control group received 5 grams of the placebo. Dietary habits and physical activity levels remained unchanged in both groups during the study. The inclusion criteria were strict to ensure the robustness of the study: the subjects had to have moderate hyperglycemia, hyperglycemia 2 hours after glucose dose (OGTT, Oral Glucose Tolerance Test), abdominal obesity and hypertriglyceridemia. With such characteristics, the included subjects were particularly at risk of fast and pejorative evolution. Analyses were conducted on 51 subjects, 13 in the placebo group and 38 in the VALEDIA® group, according to the unbalanced study design.

Main characteristics of the study population:
Age:
57.1 years old
Gender: 35 women and 16 men
Body Mass Index: 31.3 Kg/m2
Fasting glycemia: 1.26 g/L
2h-glycemia (OGTT): 1.85 g/L
Blood triglycerides: 1.78 g/L

• Main criterion met:

VALEDIA ® significantly reduced fasting blood glucose levels, compared to the placebo, after 6 months (p<0.05).

 

Fasting glycemia (g/L)

 

6 months variation (g/L)

Variation VALEDIA®
vs placebo 2

Placebo (n=13 subjects)

+ 0.09 (± 0.04)

- 9.3%

VALEDIA® (n=38 subjects)

- 0.04 (± 0.02)

 

Mean values (± SEM)

 

Moderate fasting hyperglycemia is the main risk factor for type 2 diabetes identified in people with prediabetes. With these results, VALBIOTIS defines the reduction of fasting blood glucose levels as the primary endpoint of the last two clinical studies that will be used to support requests for health claims in Europe, the United States and Canada.

• Secondary criteria met:

VALEDIA® significantly reduces blood glucose levels after 2 hours (post-prandial blood glucose), the second risk factor for type 2 diabetes, compared to the placebo (p<0.05).

 

2 hours OGTT glycemia (g/L)

 

6 months variation (g/L)

Variation VALEDIA®
vs placebo 2

Placebo (n=13 subjects)

+ 0.32 (± 0.17)

- 22.5%

VALEDIA® (n=38 subjects)

- 0.02 (± 0.07)

 

Mean values (± SEM)

 

VALEDIA® significantly reduced two anthropometric parameters, compared to the placebo: body weight (p< 0.05) and waist circumference (p< 0.001).

 

Body weight (Kg)

 

6 months variation (g/L)

Variation VALEDIA®
vs placebo 3

Placebo (n=13 subjects)

+ 1.83 (± 0.57)

- 1.9 Kg

VALEDIA® (n=38 subjects)

- 0.07 (± 0.42)

 

Mean values (± SEM)

 

 

Waist circumference (cm)

 

6 months variation (cm)

Variation VALEDIA®
vs placebo 3

Placebo (n=13 subjects)

+ 2.81 (± 0.65)

- 4.48 cm

VALEDIA® (n=38 subjects)

- 1.67 (± 0.73)

 

Mean values (± SEM)

 

Furthermore, safety data confirm that this plant-based product achieves perfect tolerance.

For Sébastien PELTIER, CEO of VALBIOTIS "The results of this clinical Phase IIA study exceed our expectations. They demonstrate that TOTUM-63, the active substance of VALEDIA®, reduces the two main risk factors for type 2 diabetes in people with prediabetes. This success validates the concomitant launch of the last two clinical studies for VALEDIA® to obtain the first health claims for the risk reduction of type 2 diabetes, in Europe and in North America. This major milestone strengthens our discussions with potential partners for marketing VALEDIA®. This is a critical milestone for VALBIOTIS: we have now scientifically validated in humans the efficacy of our new plant-based approach to prevent metabolic diseases. We would like to thank our teams, partners and shareholders. "

About TOTUM-63, the active substance of VALEDIA®

Prediabetes is an increasingly prevalent public health problem worldwide and recognized by international organizations such as the WHO, the American Diabetes Association and the International Diabetes Federation. Without effective treatment, 70% to 90% of prediabetic patients will develop type 2 diabetes.

VALEDIA® is the first clinically validated product specifically designed to help prediabetics to reduce the risk of developing type 2 diabetes. VALEDIA® is the only product that contains the active substance TOTUM-63, a unique and patented combination of 5 plant extracts that act synergistically to target the physiopathological mechanisms of type 2 diabetes.

TOTUM-63 has already shown perfect tolerance and safety during a Phase I/II clinical study conducted in healthy volunteers. The results of the first international randomized placebo-controlled study showed that TOTUM-63 reduces fasting blood glucose levels and blood glucose after 2 hours, two risk factors for type 2 diabetes in people with prediabetes.

All the results from the Phase IIA study, as well as all key company information are available in the updated corporate presentation, available here: www.valbiotis.com/en/documents/

ABOUT VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for major players in the health care sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.

VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including La Rochelle University, the CNRS and Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled VALBIOTIS to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and an American office in Boston (MA).

VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

Find out more about VALBIOTIS:
http://valbiotis.com/

Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL

Disclaimer

This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 5 April 2017 (application number I.17-012), as well as in the 2018 annual financial report, filed with AMF on 8 March 2019. This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.

1 ID-RCB Number: 2016-A00484-47
2 Difference of the means of individual variations expressed in %.
3 Difference of the means of individual variations.

Contact information

VALBIOTIS 
CORPORATE COMMUNICATION 
Carole Rocher / 
Marc Delaunay 
+33 5 46 28 62 58 
medias@valbiotis.com

FINANCIAL COMMUNICATION 
ACTIFIN 
Stéphane Ruiz 
+33 1 56 88 11 14 
sruiz@actifin.fr

MEDIA RELATIONS 
MADIS PHILEO 
Guillaume De Chamisso 
+33 6 85 91 32 56 
guillaume.dechamisso@madisphileo.com

UNITED STATES 
SOLEBURY TROUT 
Rebecca John / Patrick Till 
+1 646 378 2935 
rjohn@troutgroup.com 
ptill@troutgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Topcon to Attend EURETINA 2019 Meeting21.8.2019 07:00:00 EESTPress release

Topcon Europe Medical, a leading provider of medical devices and software solutions for the European eye care community, is excited to announce its participation in EURETINA 2019, the European Society of Retinal Specialists’ annual congress, which has become internationally renowned as the largest retina meeting worldwide. On 5-8 September, thousands of vitreoretinal and macula specialists will gather at the Palais des Congrès de Paris in France to share information on the latest trends and advances in vitreoretinal surgery and the diagnosis and treatment of retinal diseases including macular degeneration and diabetic retinopathy. Topcon will be located in the Exhibit Hall, Level 2 at Booth #219 and will showcase its latest innovative technology solutions for today’s retina specialists including the Triton Swept Source OCT, the newly released Maestro Fully Automated OCT with Angiography, Artificial Intelligence systems, the all new Topcon Signal Hand-held Camera, and the PASCAL Laser S

IFF to Present at Barclays Global Consumer Staples Conference September 520.8.2019 23:15:00 EESTPress release

Regulatory News: IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition & ingredients today announced that the Company’s management will speak at the Barclays Global Consumer Staples Conference in Boston, Massachusetts, on Thursday, Sept 5, 2019 at 2:15 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/ho

Novalis LifeSciences Launches its First Life Science Investment Fund with $85 Million20.8.2019 19:29:00 EESTPress release

August 20th, 2019, Novalis LifeSciences, an investment and advisory firm for the Life Science industry, announced today that it has raised $85M in capital for its first fund - Novalis LifeSciences Investments I, L.P. Novalis LifeSciences is focused on highly innovative Life Science companies. On the occasion of closing the first fund, Marijn E. Dekkers, founder and chairman, said: “This first fund is a growth-oriented fund that will invest in 8-12 companies that are commercializing breakthrough technologies in various segments of the Life Science industry. This includes drug discovery, life science tools, genomics, synthetic biology, diagnostics, and agricultural biotechnology – all areas with huge unmet needs and exciting opportunities for investors”. About Novalis LifeSciences Novalis Lifesciences LLC, is a globally acting venture capital firm focused on breakthrough technologies in Life Science. Founded and managed by Dr. Marijn E. Dekkers, current chairman of Unilever and former ch

Bermuda Tech Week 2019 to Celebrate Innovation and Explore Opportunities for Growth20.8.2019 17:27:00 EESTPress release

Registration is under way and filling fast for Bermuda Tech Week 2019 which will take place at the Hamilton Princess & Beach Club from October 14-18, 2019. The programme of insightful and engaging events will explore future opportunities and challenges presented by emerging technologies such as artificial intelligence, blockchain, digital assets, insurtech and virtual reality. It will showcase Bermuda’s ongoing success in creating a welcoming, stable and well-regulated environment where technology and start-up companies can thrive. “Bermuda has a long history of innovation so we understand and recognise the power of technology to positively impact both the economy and society,” said Bermuda Premier David Burt. “Over the past two years, we have built on our strength as a global leader in regulating the risks associated with the global insurance industry to develop a clear regulatory framework around managing the risks associated with Fintech. Our progressive approach has drawn accolades

Limelight Networks Expands Developer Toolkit With New API and Portal Enhancements20.8.2019 17:25:00 EESTPress release

Limelight Networks, Inc. (Nasdaq: LLNW), a leading provider of edge cloud services, today announced it has expanded the management and configuration capabilities of its suite of services with new Application Programming Interfaces (APIs) and web portal offerings. With these new capabilities in addition to existing APIs and Software Development Kits, developers now have more power to manage and monitor services across Limelight’s edge cloud platform. According to an IDC surveyi, more than half the organizations surveyed have already adopted DevOps practices, with an additional 20 percent planning to do so in the next 12 months. To help organizations meet these demands, Limelight has introduced expanded API capabilities to provide developers with access to the full set of configuration options available across its content delivery services. Limelight’s new Configuration API enables developers to configure Limelight services and programmatically integrate them into their workflows. It exp

Andersen Global Enters Zimbabwe20.8.2019 16:30:00 EESTPress release

Andersen Global announced it has signed a collaboration agreement with Chimwamurombe Legal Practice (Zenas) in Zimbabwe. Andersen Global has built a presence in over 14 African countries in just under two years. Zenas was founded in 2015 and now has a team of 11 professionals who provide legal services to individuals, organizations, institutions and corporations. With a specialty of serving small to medium enterprises, they offer solutions in mining and construction, commercial, debt recovery, property law, labor law, family law, tax, technology, telecommunications, media and intellectual property law, and criminal litigation. “When we started, we set out to be the most sought-after, trusted legal firm in Zimbabwe,” said Fungai Chimwamurombe, Zenas Office Managing Director. “These values line up very closely with those firms in the Andersen Global international organization. We are happy to join a team of professionals that is equally committed to treating clients like family and deliv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom